Kidney Cancer Trial: The RadiCaL Study

For more info, visit: https://www.primrmed.com/cancer-clini... This trial is studying whether adding radium-223 dichloride to the usual treatment of cabozantinib, can improve outcomes in patients with kidney cancer that has spread to bones. Cabozantinib may stop the growth of cancer cells. Radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells, helping to lessen pain and symptoms from renal cell cancer that has spread to the bone compared to cabozantinib alone.